Get the Stockscreener App
440.49
1.36%
5.93
After Hours:
440.49
Alnylam Pharmaceuticals Inc stock is traded at $440.49, with a volume of 700.44K.
It is up +1.36% in the last 24 hours and down -2.55% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$434.56
Open:
$431.78
24h Volume:
700.44K
Relative Volume:
0.62
Market Cap:
$57.74B
Revenue:
$3.21B
Net Income/Loss:
$43.57M
P/E Ratio:
1,831.56
EPS:
0.2405
Net Cash Flow:
$221.36M
1W Performance:
-2.02%
1M Performance:
-2.55%
6M Performance:
+63.26%
1Y Performance:
+61.35%
1-Day Range:
$429.00
$445.50
1-Week Range:
$417.00
$459.77
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
440.49 | 57.41B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.25 | 105.80B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
646.87 | 67.70B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.01 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.68 | 39.86B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Regression analysis insights on Alnylam Pharmaceuticals Inc. performanceDividend Hike & Weekly Consistent Profit Watchlists - newser.com
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboardsBull Run & Safe Capital Growth Stock Tips - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stock2025 Big Picture & AI Forecasted Stock Moves - newser.com
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersTrade Performance Summary & Verified High Yield Trade Plans - newser.com
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumJuly 2025 Closing Moves & Momentum Based Trading Signals - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Market Volume Summary & Fast Exit and Entry Strategy Plans - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver shareholder valueRate Cut & Weekly Sector Rotation Insights - fcp.pa.gov.br
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.July 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Biggest Moves & Short-Term Trading Alerts - newser.com
Published on: 2025-11-05 21:04:23 - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockStock Surge & Stock Portfolio Risk Control - newser.com
Published on: 2025-11-05 12:16:44 - newser.com
Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025? - simplywall.st
Will Alnylam Pharmaceuticals Inc. continue its uptrendBond Market & AI Based Buy/Sell Signal Reports - newser.com
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Burney Co. - MarketBeat
Alnylam Pharma (ALNY) Receives a Rating Update from a Top Analyst - The Globe and Mail
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureMarket Movers & Risk Controlled Stock Alerts - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsMarket Trend Report & Reliable Entry Point Alerts - newser.com
Simon Quick Advisors LLC Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million - MarketScreener
Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds - Yahoo Finance
(ALNY) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Alnylam (NASDAQ: ALNY) to present Nov 10 & Nov 19 at UBS and Jefferies; live webcasts - Stock Titan
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Hussman Strategic Advisors Inc. Sells 2,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryInflation Watch & Low Drawdown Investment Ideas - newser.com
Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assetmark Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Review & Target Return Focused Picks - newser.com
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewswire Inc.
Tredje AP fonden Has $3.98 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Dropped from Goldman Sachs Conviction List - GuruFocus
Has Alnylam Pharmaceuticals Inc. found a price floorJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):